[ad_1]

BENGALURU: Biocon Biologics, a subsidiary of biopharmaceutical company Biocon, has partnered with Voluntis to develop and distribute digital therapeutics for people with diabetes.The licensing agreement, signed by Biocon Biologics’ subsidiary Biocon Sdn Bhd – Malaysia and the France-based digital therapeutics company, would make Biocon Biologics one of the first insulin companies to offer a US Food and Drug Administration-cleared digital therapeutic product – Insulia – for Type 2 diabetes patients across several global markets, Biocon said in a statement.Insulia provides automated insulin dose recommendations and coaching messages for people with diabetes, while enabling the healthcare team to remotely monitor their progress.A healthcare practitioner prescribes Insulia using a dedicated web portal and sets up the treatment plan rules that will adjust basal insulin dosing based on the person’s specific needs.The user then receives an activation code to get started with a personalised app. Once downloaded, the app uses blood glucose readings and any hypo symptoms to recommend doses in real-time.

[ad_2]

Source link
[ad_2]